{"nctId":"NCT01949155","briefTitle":"OTO-201 for the Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement","startDateStruct":{"date":"2013-11"},"conditions":["Otitis Media With Effusion"],"count":266,"armGroups":[{"label":"OTO-201","type":"EXPERIMENTAL","interventionNames":["Drug: OTO-201"]},{"label":"Sham","type":"SHAM_COMPARATOR","interventionNames":["Drug: Sham"]}],"interventions":[{"name":"OTO-201","otherNames":[]},{"name":"Sham","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria includes, but is not limited to:\n\n* Subject is a male or female aged 6 months to 17 years, inclusive\n* Subject has a clinical diagnosis of bilateral middle ear effusion requiring tympanostomy tube placement\n* Subject's caregiver is willing to comply with the protocol and attend all study visits\n\nExclusion Criteria includes, but is not limited to:\n\n* Subject has a history of prior ear or mastoid surgery, not including myringotomy or myringotomy with tympanostomy tube placement\n* Subject has a history of sensorineural hearing loss\n* Subject has a history of chronic or recurrent bacterial infections other than otitis media that likely will require treatment with antibiotics during the course of the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Months","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Who Were Treatment Failures.","description":"Cumulative proportion of treatment failures:\n\nThe efficacy endpoint for both trials was the cumulative proportion of study treatment failures through Day 15, defined as the occurrence of any of the following events: otorrhea as determined by a blinded assessor on or after 3 days post-surgery, otic or systemic antibacterial drug use for any reason any time post-surgery, as well as patients who missed visits or were lost-to-follow-up.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.3","spread":null},{"groupId":"OG001","value":"45.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Evaluation of Adverse Events, Otoscopic Exams, Audiometry and Tympanometry","description":"Safety variables included the frequency of adverse events (AEs) and results from otoscopic examinations, tympanometry, audiometry measurements.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":null},{"groupId":"OG001","value":"2.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":null},{"groupId":"OG001","value":"3.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.0","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.0","spread":null},{"groupId":"OG001","value":"96.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.9","spread":null},{"groupId":"OG001","value":"87.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.2","spread":null},{"groupId":"OG001","value":"84.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Microbiological Response","description":"Subjects whose samples tested positive for bacteria in either or both ears at baseline with documented eradication or presumed eradication post-baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83","spread":null},{"groupId":"OG001","value":"48","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":178},"commonTop":["Pyrexia","Procedural pain","Upper respiratory tract infection","Teething","Cough"]}}}